{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:35:31Z","timestamp":1791858931366,"version":"4.3.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02184-4","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T10:04:51Z","timestamp":1656929091000},"page":"3896-3915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice"],"prefix":"10.1007","volume":"39","author":[{"given":"Seppo","family":"Meri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Cofiell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"2184_CR1","doi-asserted-by":"crossref","unstructured":"Timmermans SAMEG, van Paassen P. The syndromes of thrombotic microangiopathy: a critical appraisal on complement dysregulation. J Clin Med. 2021;10(14):3034.","DOI":"10.3390\/jcm10143034"},{"issue":"1","key":"2184_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2010111130","volume":"23","author":"K El Karoui","year":"2012","unstructured":"El Karoui K, Hill GS, Karras A, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol. 2012;23(1):137\u201348.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2184_CR3","first-page":"411","volume":"21","author":"SA De Serres","year":"2010","unstructured":"De Serres SA, Isenring P. Renal thrombotic microangiopathy revisited: when a lesion is not a clinical finding. Saudi J Kidney Dis Transpl. 2010;21(3):411\u20136.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"6","key":"2184_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ejim.2013.05.009","volume":"24","author":"S Meri","year":"2013","unstructured":"Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24(6):496\u2013502.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2184_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ckj\/sfy066","volume":"12","author":"BE Berger","year":"2018","unstructured":"Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J. 2018;12(3):338\u201347.","journal-title":"Clin Kidney J"},{"issue":"2","key":"2184_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/1078155216628324","volume":"23","author":"G Garcia","year":"2016","unstructured":"Garcia G, Atallah JP. Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract. 2016;23(2):135\u201342.","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"2184_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1200\/JOP.2016.012096","volume":"12","author":"JM Morton","year":"2016","unstructured":"Morton JM, George JN. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J Oncol Practice. 2016;12(6):523\u201330.","journal-title":"J Oncol Practice"},{"issue":"8","key":"2184_CR8","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","volume":"56","author":"JA Young","year":"2021","unstructured":"Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transpl. 2021;56(8):1805\u201317.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"2184_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","volume":"127","author":"S Jodele","year":"2016","unstructured":"Jodele S, Zhang K, Zou F, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127(8):989\u201396.","journal-title":"Blood"},{"issue":"3","key":"2184_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","volume":"29","author":"S Jodele","year":"2015","unstructured":"Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29(3):191\u2013204.","journal-title":"Blood Rev"},{"issue":"1","key":"2184_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","volume":"5","author":"CE Dandoy","year":"2020","unstructured":"Dandoy CE, Rotz S, Alonso PB, et al. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv. 2020;5(1):1\u201311.","journal-title":"Blood Adv"},{"issue":"4","key":"2184_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bmt.2009.230","volume":"45","author":"E Willems","year":"2010","unstructured":"Willems E, Baron F, Seidel L, Fr\u00e8re P, Fillet G, Beguin Y. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transpl. 2010;45(4):689\u201393.","journal-title":"Bone Marrow Transpl"},{"key":"2184_CR13","doi-asserted-by":"crossref","unstructured":"Dvorak CC, Higham C, Shimano KA. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant tecipients: a practical approach to diagnosis and management. Front Pediatr. 2019;7(133).","DOI":"10.3389\/fped.2019.00133"},{"issue":"8","key":"2184_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/17474086.2021.1960816","volume":"14","author":"S Jodele","year":"2021","unstructured":"Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol. 2021;14(8):751\u201363.","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"2184_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13371","volume":"32","author":"E Gavriilaki","year":"2018","unstructured":"Gavriilaki E, Sakellari I, Batsis I, et al. Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transpl. 2018;32(9):e13371.","journal-title":"Clin Transpl"},{"issue":"11","key":"2184_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.bbmt.2018.05.010","volume":"24","author":"M Postalcioglu","year":"2018","unstructured":"Postalcioglu M, Kim HT, Obut F, et al. Impact of thrombotic microangiopathy on renal outcomes and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24(11):2344\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2184_CR17","doi-asserted-by":"crossref","unstructured":"Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I\u2014molecular mechanisms of activation and regulation. Front Immunol. 2015;6(262).","DOI":"10.3389\/fimmu.2015.00262"},{"key":"2184_CR18","doi-asserted-by":"crossref","unstructured":"Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6(257).","DOI":"10.3389\/fimmu.2015.00257"},{"issue":"1","key":"2184_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","volume":"34","author":"K Oikonomopoulou","year":"2012","unstructured":"Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement\u2013their role in inflammation. Semin Immunopathol. 2012;34(1):151\u201365.","journal-title":"Semin Immunopathol"},{"key":"2184_CR20","first-page":"71","volume":"632","author":"U Amara","year":"2008","unstructured":"Amara U, Rittirsch D, Flierl M, et al. Interaction between the coagulation and complement system. Adv Exp Med Biol. 2008;632:71\u20139.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2184_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00281-017-0644-y","volume":"40","author":"J Killick","year":"2018","unstructured":"Killick J, Morisse G, Sieger D, Astier AL. Complement as a regulator of adaptive immunity. Semin Immunopathol. 2018;40(1):37\u201348.","journal-title":"Semin Immunopathol"},{"key":"2184_CR22","doi-asserted-by":"publisher","unstructured":"Bekassy Z, Lopatko Fagerstr\u00f6m I, Bader M, Karpman D. Crosstalk between the renin\u2013angiotensin, complement and kallikrein\u2013kinin systems in inflammation. Nat Rev Immunol. 2021. https:\/\/doi.org\/10.1038\/s41577-021-00634-8.","DOI":"10.1038\/s41577-021-00634-8"},{"issue":"3","key":"2184_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","volume":"138","author":"M Harboe","year":"2004","unstructured":"Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138(3):439\u201346.","journal-title":"Clin Exp Immunol"},{"key":"2184_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","volume":"104","author":"PJ Lachmann","year":"2009","unstructured":"Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol. 2009;104:115\u201349.","journal-title":"Adv Immunol"},{"issue":"9","key":"2184_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1096\/fj.02-0737com","volume":"17","author":"T Monsinjon","year":"2003","unstructured":"Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 2003;17(9):1003\u201314.","journal-title":"FASEB J"},{"key":"2184_CR26","doi-asserted-by":"crossref","unstructured":"Gonzalez SF, Lukacs-Kornek V, Kuligowski MP, et al. Complement-dependent transport of antigen into B cell follicles. J Immunol. 2010;185(5):2659\u201364.","DOI":"10.4049\/jimmunol.1000522"},{"issue":"6","key":"2184_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508\u201330.","journal-title":"Semin Nephrol"},{"issue":"21","key":"2184_CR28","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","volume":"125","author":"R Cofiell","year":"2015","unstructured":"Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125(21):3253\u201362.","journal-title":"Blood"},{"issue":"3","key":"2184_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2353\/ajpath.2007.070166","volume":"171","author":"MM Markiewski","year":"2007","unstructured":"Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171(3):715\u201327.","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"2184_CR30","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1111\/jth.12950","volume":"13","author":"EM Conway","year":"2015","unstructured":"Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost. 2015;13(Suppl 1):S121\u201332.","journal-title":"J Thromb Haemost"},{"key":"2184_CR31","doi-asserted-by":"crossref","unstructured":"Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794\u2013802.","DOI":"10.4049\/jimmunol.177.7.4794"},{"issue":"4","key":"2184_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.it.2007.02.006","volume":"28","author":"MM Markiewski","year":"2007","unstructured":"Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184\u201392.","journal-title":"Trends Immunol"},{"key":"2184_CR33","doi-asserted-by":"crossref","unstructured":"Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185(9):5628\u201336.","DOI":"10.4049\/jimmunol.0903678"},{"issue":"4","key":"2184_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035690","volume":"7","author":"K Hess","year":"2012","unstructured":"Hess K, Ajjan R, Phoenix F, Dob\u00f3 J, G\u00e1l P, Schroeder V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS ONE. 2012;7(4): e35690.","journal-title":"PLoS ONE"},{"issue":"6","key":"2184_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20041497","volume":"201","author":"I Del Conde","year":"2005","unstructured":"Del Conde I, Cr\u00faz MA, Zhang H, L\u00f3pez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201(6):871\u20139.","journal-title":"J Exp Med"},{"issue":"8","key":"2184_CR36","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1538-7836.2008.03034.x","volume":"6","author":"OA Hamad","year":"2008","unstructured":"Hamad OA, Ekdahl KN, Nilsson PH, et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thrombosis Haemostasis. 2008;6(8):1413\u201321.","journal-title":"J Thrombosis Haemostasis"},{"issue":"1","key":"2184_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12468","volume":"274","author":"P Garred","year":"2016","unstructured":"Garred P, Genster N, Pilely K, et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev. 2016;274(1):74\u201397.","journal-title":"Immunol Rev"},{"issue":"3","key":"2184_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.smim.2016.04.006","volume":"28","author":"KN Ekdahl","year":"2016","unstructured":"Ekdahl KN, Huang S, Nilsson B, Teramura Y. Complement inhibition in biomaterial- and biosurface-induced thromboinflammation. Semin Immunol. 2016;28(3):268\u201377.","journal-title":"Semin Immunol"},{"issue":"3","key":"2184_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MBC.0000000000000720","volume":"29","author":"EM Conway","year":"2018","unstructured":"Conway EM. Complement-coagulation connections. Blood Coagul Fibrinolysis. 2018;29(3):243\u201351.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"2184_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41423-018-0024-0","volume":"16","author":"CM de Bont","year":"2019","unstructured":"de Bont CM, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol. 2019;16(1):19\u201327.","journal-title":"Cell Mol Immunol"},{"key":"2184_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-030-44518-8_2","volume":"1263","author":"H Huang","year":"2020","unstructured":"Huang H, Zhang H, Onuma AE, Tsung A. Neutrophil elastase and neutrophil extracellular traps in the tumor microenvironment. Adv Exp Med Biol. 2020;1263:13\u201323.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2184_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/cei.12654","volume":"181","author":"H Wang","year":"2015","unstructured":"Wang H, Wang C, Zhao MH, Chen M. Neutrophil extracellular traps can activate alternative complement pathways. Clin Exp Immunol. 2015;181(3):518\u201327.","journal-title":"Clin Exp Immunol"},{"key":"2184_CR43","doi-asserted-by":"crossref","unstructured":"Sartain SE, Turner NA, Moake JL. TNF regulates essential alternative complement pathway components and impairs activation of protein C in human glomerular endothelial cells. J Immunol. 2016;196(2):832\u201345.","DOI":"10.4049\/jimmunol.1500960"},{"issue":"4","key":"2184_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00005-013-0228-z","volume":"61","author":"C Sj\u00f8qvist","year":"2013","unstructured":"Sj\u00f8qvist C, Snarski E. Inflammatory markers in patients after hematopoietic stem cell transplantation. Arch Immunol Ther Exp. 2013;61(4):301\u20137.","journal-title":"Arch Immunol Ther Exp"},{"issue":"8","key":"2184_CR45","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bbmt.2016.04.005","volume":"22","author":"Z Li","year":"2016","unstructured":"Li Z, Rubinstein SM, Thota R, et al. Immune-mediated complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22(8):1368\u201375.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2184_CR46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/bmt.2015.308","volume":"51","author":"S Chaturvedi","year":"2016","unstructured":"Chaturvedi S, Neff A, Nagler A, Savani U, Mohty M, Savani BN. Venous thromboembolism in hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 2016;51(4):473\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2184_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","volume":"124","author":"S Jodele","year":"2014","unstructured":"Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645\u201353.","journal-title":"Blood"},{"issue":"13","key":"2184_CR48","first-page":"1049","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135(13):1049\u201357.","journal-title":"Blood"},{"issue":"12","key":"2184_CR49","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","volume":"122","author":"S Jodele","year":"2013","unstructured":"Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003\u20137.","journal-title":"Blood"},{"issue":"1","key":"2184_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40164-021-00249-8","volume":"10","author":"E Gavriilaki","year":"2021","unstructured":"Gavriilaki E, Ho VT, Schwaeble W, et al. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol. 2021;10(1):57.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"2184_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/bmt.2017.207","volume":"53","author":"J Khosla","year":"2018","unstructured":"Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transpl. 2018;53(2):129\u201337.","journal-title":"Bone Marrow Transpl"},{"key":"2184_CR52","doi-asserted-by":"crossref","unstructured":"Farrar C, Asgari E, Schwaeble W, Sacks S. Which pathways trigger the role of complement in ischaemia\/reperfusion injury? Front Immunol. 2012;3.","DOI":"10.3389\/fimmu.2012.00341"},{"issue":"11","key":"2184_CR53","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.imbio.2012.07.024","volume":"217","author":"WB Gorsuch","year":"2012","unstructured":"Gorsuch WB, Chrysanthou E, Schwaeble WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. Immunobiology. 2012;217(11):1026\u201333.","journal-title":"Immunobiology"},{"key":"2184_CR54","doi-asserted-by":"crossref","unstructured":"Hart ML, Ceonzo KA, Shaffer LA, et al. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol. 2005;174(10):6373\u201380.","DOI":"10.4049\/jimmunol.174.10.6373"},{"issue":"5","key":"2184_CR55","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0002-9440(10)65026-2","volume":"156","author":"CD Collard","year":"2000","unstructured":"Collard CD, V\u00e4kev\u00e4 A, Morrissey MA, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000;156(5):1549\u201356.","journal-title":"Am J Pathol"},{"issue":"1","key":"2184_CR56","first-page":"429","volume":"286","author":"M Buerke","year":"1998","unstructured":"Buerke M, Pr\u00fcfer D, Dahm M, Oelert H, Meyer J, Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther. 1998;286(1):429\u201338.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2184_CR57","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1084\/jem.183.5.2343","volume":"183","author":"MR Weiser","year":"1996","unstructured":"Weiser MR, Williams JP, Moore FD Jr, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med. 1996;183(5):2343\u20138.","journal-title":"J Exp Med"},{"issue":"5","key":"2184_CR58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1365-3083.2001.00908.x","volume":"53","author":"H Liu","year":"2001","unstructured":"Liu H, Jensen L, Hansen S, et al. Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. Scand J Immunol. 2001;53(5):489\u201397.","journal-title":"Scand J Immunol"},{"issue":"3","key":"2184_CR59","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2249.2004.02645.x","volume":"138","author":"MD Schafranski","year":"2004","unstructured":"Schafranski MD, Stier A, Nisihara R, Messias-Reason IJT. Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: a beneficial role for MBL deficiency. Clin Exp Immunol. 2004;138(3):521\u20135.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2184_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12950-020-00257-1","volume":"17","author":"S Jacobson","year":"2020","unstructured":"Jacobson S, Larsson P, \u00c5berg A-M, Johansson G, Wins\u00f6 O, S\u00f6derberg S. Levels of mannose-binding lectin (MBL) associates with sepsis-related in-hospital mortality in women. J Inflamm. 2020;17(1):28.","journal-title":"J Inflamm"},{"issue":"1","key":"2184_CR61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cei.13497","volume":"203","author":"S Elhadad","year":"2021","unstructured":"Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021;203(1):96\u2013104.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"2184_CR62","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1681\/ASN.2014050429","volume":"26","author":"JS Chua","year":"2015","unstructured":"Chua JS, Baelde HJ, Zandbergen M, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol. 2015;26(9):2239\u201347.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2184_CR63","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","volume":"4","author":"S Jodele","year":"2020","unstructured":"Jodele S, Medvedovic M, Luebbering N, et al. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4(6):1166\u201377.","journal-title":"Blood Adv"},{"issue":"2","key":"2184_CR64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/00003495-200969020-00004","volume":"69","author":"CM Choi","year":"2009","unstructured":"Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation. Drugs. 2009;69(2):183\u201398.","journal-title":"Drugs"},{"issue":"3","key":"2184_CR65","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","volume":"55","author":"T Luft","year":"2020","unstructured":"Luft T, Benner A, Terzer T, et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transpl. 2020;55(3):553\u201361.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2184_CR66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","volume":"22","author":"S Jodele","year":"2016","unstructured":"Jodele S, Fukuda T, Mizuno K, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow. 2016;22(2):307\u201315.","journal-title":"Biol Blood Marrow"},{"key":"2184_CR67","doi-asserted-by":"crossref","unstructured":"Ekdahl KN, Persson B, Mohlin C, Sandholm K, Skattum L, Nilsson B. Interpretation of serological complement biomarkers in disease. Front Immunol. 2018;9(2237).","DOI":"10.3389\/fimmu.2018.02237"},{"key":"2184_CR68","doi-asserted-by":"crossref","unstructured":"Frazer-Abel A, Kirschfink M, Proh\u00e1szka Z. Expanding horizons in complement analysis and quality control. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.697313"},{"issue":"3","key":"2184_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28070","volume":"67","author":"S Sartain","year":"2020","unstructured":"Sartain S, Shubert S, Wu M-F, Wang T, Martinez C. The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy. Pediatr Blood Cancer. 2020;67(3): e28070.","journal-title":"Pediatr Blood Cancer"},{"key":"2184_CR70","doi-asserted-by":"crossref","unstructured":"Yamada R, Nemoto T, Ohashi K, et al. Distribution of transplantation-associated thrombotic microangiopathy (TA-TMA) and comparison between renal TA-TMA and intestinal TA-TMA: autopsy study. Biol Blood Marrow Transplant. 2020;26(1):178\u201388.","DOI":"10.1016\/j.bbmt.2019.08.025"},{"issue":"9","key":"2184_CR71","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.bmt.1705976","volume":"41","author":"BS Cho","year":"2008","unstructured":"Cho BS, Min CK, Eom KS, et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2008;41(9):813\u201320.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2184_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1620\/tjem.227.31","volume":"227","author":"M Yamada-Fujiwara","year":"2012","unstructured":"Yamada-Fujiwara M, Miyamura K, Fujiwara T, et al. Diagnosis of intestinal graft-versus-host disease and thrombotic microangiopathy after allogeneic stem cell transplantation. Tohoku J Exp Med. 2012;227(1):31\u20137.","journal-title":"Tohoku J Exp Med"},{"issue":"11","key":"2184_CR73","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.bbmt.2015.06.016","volume":"21","author":"J El-Bietar","year":"2015","unstructured":"El-Bietar J, Warren M, Dandoy C, et al. Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21(11):1994\u20132001.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2184_CR74","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/bmt.2008.419","volume":"44","author":"Y Inamoto","year":"2009","unstructured":"Inamoto Y, Ito M, Suzuki R, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transpl. 2009;44(1):43\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2184_CR75","doi-asserted-by":"crossref","unstructured":"Saidu NEB, Bonini C, Dickinson A, et al. New approaches for the treatment of chronic graft-versus-host disease: current status and future directions. Front Immunol. 2020;11(2625).","DOI":"10.3389\/fimmu.2020.578314"},{"issue":"11","key":"2184_CR76","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.5858\/arpa.2016-0599-RA","volume":"141","author":"M Warren","year":"2017","unstructured":"Warren M, Jodele S, Dandoy C, et al. A complete histologic approach to gastrointestinal biopsy from hematopoietic stem cell transplant patients with evidence of transplant-associated gastrointestinal thrombotic microangiopathy. Arch Pathol Lab Med. 2017;141(11):1558\u201366.","journal-title":"Arch Pathol Lab Med"},{"issue":"20","key":"2184_CR77","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/bloodadvances.2018020321","volume":"2","author":"SA Wall","year":"2018","unstructured":"Wall SA, Zhao Q, Yearsley M, et al. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2(20):2619\u201328.","journal-title":"Blood Adv"},{"key":"2184_CR78","doi-asserted-by":"crossref","unstructured":"Bonifazi F, Barbato F, Ravaioli F, et al. Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489.","DOI":"10.3389\/fimmu.2020.00489"},{"issue":"2","key":"2184_CR79","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2018;53(2):138\u201345.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2184_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11899-018-0435-0","volume":"13","author":"LE Horton","year":"2018","unstructured":"Horton LE, Haste NM, Taplitz RA. Rethinking antimicrobial prophylaxis in the transplant patient in the world of emerging resistant organisms-where are we today? Curr Hematol Malig Rep. 2018;13(1):59\u201367.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"2184_CR81","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1824-7288-36-14","volume":"36","author":"A No\u00e8","year":"2010","unstructured":"No\u00e8 A, Cappelli B, Biffi A, et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr. 2010;36(1):14.","journal-title":"Ital J Pediatr"},{"issue":"10","key":"2184_CR82","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.25922","volume":"95","author":"C Heybeli","year":"2020","unstructured":"Heybeli C, Sridharan M, Alkhateeb HB, et al. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2020;95(10):1170\u20139.","journal-title":"Am J Hematol"},{"issue":"4","key":"2184_CR83","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1182\/bloodadvances.2021004933","volume":"6","author":"S Vasu","year":"2022","unstructured":"Vasu S, Bostic M, Zhao Q, et al. Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults. Blood Adv. 2022;6(4):1342\u20139.","journal-title":"Blood Adv"},{"issue":"9","key":"2184_CR84","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","volume":"99","author":"FS de Fontbrune","year":"2015","unstructured":"de Fontbrune FS, Galambrun C, Sirvent A, et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99(9):1953\u20139.","journal-title":"Transplantation"},{"issue":"9","key":"2184_CR85","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2016.87","volume":"51","author":"S Vasu","year":"2016","unstructured":"Vasu S, Wu H, Satoskar A, et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transpl. 2016;51(9):1241\u20134.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2184_CR86","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13127","volume":"101","author":"J Rudoni","year":"2018","unstructured":"Rudoni J, Jan A, Hosing C, Aung F, Yeh J. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol. 2018;101(3):389\u201398.","journal-title":"Eur J Haematol"},{"issue":"12","key":"2184_CR87","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","volume":"23","author":"SR Bohl","year":"2017","unstructured":"Bohl SR, Kuchenbauer F, von Harsdorf S, et al. Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy. Biol Blood Marrow Transpl. 2017;23(12):2172\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2184_CR88","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1111\/trf.14263","volume":"57","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 2017;57(11):2775\u201381.","journal-title":"Transfusion"},{"issue":"1","key":"2184_CR89","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41409-018-0256-8","volume":"54","author":"ME Mart\u00ednez-Mu\u00f1oz","year":"2019","unstructured":"Mart\u00ednez-Mu\u00f1oz ME, For\u00e9s R, Lario A, et al. Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy. Bone Marrow Transpl. 2019;54(1):142\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2184_CR90","doi-asserted-by":"crossref","unstructured":"Zhang R, Zhou M, Qi J, et al. Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis. Front Immunol. 2021;11(3486).","DOI":"10.3389\/fimmu.2020.564647"},{"issue":"8","key":"2184_CR91","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","volume":"120","author":"MJ Krisinger","year":"2012","unstructured":"Krisinger MJ, Goebeler V, Lu Z, et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood. 2012;120(8):1717\u201325.","journal-title":"Blood"},{"issue":"9","key":"2184_CR92","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1055\/s-0039-1692721","volume":"119","author":"E Gavriilaki","year":"2019","unstructured":"Gavriilaki E, Chrysanthopoulou A, Sakellari I, et al. Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy. Thromb Haemost. 2019;119(9):1433\u201340.","journal-title":"Thromb Haemost"},{"key":"2184_CR93","doi-asserted-by":"crossref","unstructured":"Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022;6(5):1454\u201363.","DOI":"10.1182\/bloodadvances.2021006523"},{"key":"2184_CR94","unstructured":"FDA. Soliris\u00ae (Eculizumab) Highlights of Prescribing Information 2007 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125166s172lbl.pdf."},{"issue":"7","key":"2184_CR95","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.bbmt.2016.03.032","volume":"22","author":"S Jodele","year":"2016","unstructured":"Jodele S, Dandoy CE, Danziger-Isakov L, et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016;22(7):1337\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2184_CR96","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","volume":"20","author":"S Jodele","year":"2014","unstructured":"Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2184_CR97","doi-asserted-by":"crossref","unstructured":"Khaled SK, Boelens JJ, Cairo MS, et al. 26 - Narsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Transplant Cell Ther. 2021;27(3, Supplement):S24\u2013S6.","DOI":"10.1016\/S2666-6367(21)00052-X"},{"issue":"3","key":"2184_CR98","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1016\/j.bbmt.2016.12.192","volume":"23","author":"SK Khaled","year":"2017","unstructured":"Khaled SK, Kwong YL, Smith M, Metjian A, Whitaker S. Early results of phase\u00a0II study using OMS721 in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA). Biol Blood Marrow Transpl. 2017;23(3):S282\u20133.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2184_CR99","doi-asserted-by":"crossref","unstructured":"Khaled SK, Claes K, Goh YT, et al. Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy. J Clin Oncol. 2022:Jco2102389.","DOI":"10.1200\/JCO.21.02389"},{"key":"2184_CR100","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","volume":"10","author":"E Gavriilaki","year":"2019","unstructured":"Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangiopathies: unraveling Ariadne\u2019s thread into the labyrinth of complement therapeutics. Front Immunol. 2019;10:337.","journal-title":"Front Immunol"},{"issue":"5","key":"2184_CR101","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10875-020-00789-4","volume":"40","author":"NJ Gloude","year":"2020","unstructured":"Gloude NJ, Dandoy CE, Davies SM, et al. Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy. J Clin Immunol. 2020;40(5):699\u2013707.","journal-title":"J Clin Immunol"},{"issue":"10","key":"2184_CR102","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","volume":"130","author":"NJ Gloude","year":"2017","unstructured":"Gloude NJ, Khandelwal P, Luebbering N, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood. 2017;130(10):1259\u201366.","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02184-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02184-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02184-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T06:48:40Z","timestamp":1661323720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02184-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":102,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2184"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02184-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}